Abstract
The muscarinic cholinergic system regulates peripheral and central nervous system functions, and, thus, their potential as a therapeutic target for several neurodegenerative diseases is undoubted. A clinically applicable positron emission tomography (PET) tracer would facilitate the monitoring of disease progression, elucidate the role of muscarinic acetylcholine receptors (mAChR) in disease development and would aid to clarify the diverse natural functions of mAChR regulation throughout the nervous system, which still are largely unresolved. Still, no mAChR PET tracer has yet found broad clinical application, which demands mAChR tracers with improved imaging properties. This paper reviews strategies of mAChR PET tracer design and summarizes the binding properties and preclinical evaluation of recent mAChR tracer candidates. Furthermore, this work identifies the current major challenges in mAChR PET tracer development and provides a perspective on future developments in this area of research.
Original language | English |
---|---|
Article number | 530 |
Number of pages | 19 |
Journal | Pharmaceuticals |
Volume | 14 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2 Jun 2021 |
Austrian Fields of Science 2012
- 104015 Organic chemistry
Keywords
- ALLOSTERIC MODULATOR
- ALZHEIMER-DISEASE
- BINDING
- BIOLOGICAL EVALUATION
- CHOLINERGIC-RECEPTORS
- HUMAN BRAIN
- IN-VIVO
- LIGANDS
- MOUSE-BRAIN
- PET
- POSITRON-EMISSION-TOMOGRAPHY
- molecular imaging
- muscarinic acetylcholine receptors
- tracer development
- Molecular imaging
- Tracer development
- Muscarinic acetylcholine receptors